ADALIMUMAB-AFZB vs ADALIMUMAB-RYVK

TrumpRx is a recently launched prescription discount program that claims to lower drug prices through "Most-Favored-Nation" pricing and direct negotiations with manufacturers, allegedly forcing drugmakers to match the lowest prices available globally. I was curious whether these claims held up in pr

I am long on ATNF and there are some key details I’ve uncovered in my due diligence which might not be immediately apparent to a newcomer to this ticker. Company is targeting inflammation pain and fibrosis which are related in fascinating ways at a cellular level it takes a Phd to actually understan

After failing Remicade, Stelara, Abrilada, Entyvio and getting an Imuran & Methotrexate toxicity and resisting to steroids bc too many rounds and NO relief and severe disease, with Skyrizi, I FINALLY see a difference!!! And relief!!!!!!!!! And a light at the end of this darkness Crohn's depressi

Hi r/Hidradenitis, I’m Stage 2 with some tunnels, on weekly Abrilada injections and daily Clindamycin. After seeing Reddit posts hyping Desitin Maximum Strength Diaper Rash Cream (40% Zinc Oxide), I tried it for the first time on Sunday for abscesses in my groin, back, and a stubborn jaw abscess (my

Hi everyone. I made a reddit account specifically to connect with this community. I'm a 24F and have had uveitis since I was around 10. I was diagnosed with rheumatoid arthritis when I was 3 and got diagnosed with uveitis around 10. Since then, I have had a few eye surgeries and tried numerous amoun

I've been on Humira for the past 1.5 years and it seems to be working for me, i was taking it alongside Skyrizi after I had a temp ileostomy and have been taking it on its own for the past 6 months since I had a reversal. My GI just informed me they'll be switching me over to the biosimilar, Abrilad

I love participating in research studies that help our community! Even better when you get paid! Pillar Patient Advocates is seeking patients who are currently or previously have taken a Biosimilar medication to participate in a 45-minute web-based interview. Participants are paid $105 in appreciat

Hi everyone. I’m doing a project on Humira, and I’m getting flustered with the information that is online about the patent expiration and deferring of bio similar entry. From my understanding, the primary patent expiration date was 2016? But now I saw something about 2034? I also read about market e

I’m a 49M Crohn’s veteran, pretty new to Reddit. I’ve been on Humira for the past 10 years with fantastic results. By far the longest remission period since I was diagnosed in 1986. Last summer I had a skin cancer spot on my ear, a basal cell. Had it removed via Moh’s surgery. Now I have another spo

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Lt

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced t

* In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI * SELARSDI is the second biosimilar to launch in the U.S. under t

February 23, 2024 8:15 PM SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for intercha

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration interchangeable biosimilar to Hum

* Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis * The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection i